- Business
- PHC Holdings Corporation PHC Holdings Corporation (6523.T), headquartered in Tokyo, Japan and founded in 2014 as an independent entity following a management buyout from Hitachi Ltd., engages primarily in the development, manufacture, and sale of healthcare devices, healthcare IT solutions, and life science products and services through its subsidiaries. The company operates across three main segments: Diabetes Management, offering blood glucose monitoring systems, continuous glucose monitoring systems such as Eversense, point-of-care testing products, and digital diabetes management applications marketed in over 100 countries; Healthcare Solutions, providing electronic medical record systems, receipt computers, electronic medication history systems, pharmacy management tools, telemedicine platforms, and clinical laboratory diagnosis services mainly in Japan; and Diagnostics & Life Sciences, encompassing research equipment like low-temperature freezers, CO2 incubators, sample preservation systems, cell culture devices, cancer pathology solutions including tissue processors, microscope slides, consumables, and dyeing reagents from Epredia Holdings Ltd., as well as in vitro diagnostic reagents, immunoassay analyzers such as PATHFAST, and drug development support products. PHC Holdings maintains a global footprint with key operations in Japan, North America, Europe, and Asia, targeting healthcare providers, clinics, hospitals, pharmacies, research institutions, universities, and pharmaceutical companies. Recent developments include the integration of subsidiaries Wemex Corporation and Wemex Healthcare Systems Corporation in October 2025 to enhance healthcare IT capabilities in Japan; a memorandum of understanding signed by subsidiary Ascensia Diabetes Care in September 2025 with Senseonics Inc. to transfer commercial activities of the Eversense continuous glucose monitoring system; the launch of non-fluorine large-capacity freezer-equipped pharmaceutical refrigerators MPR-N650FH and MPR-N650FSH in November 2025 for improved drug storage; and the release of the Integrated Report 2025 alongside a revised full-year performance forecast in November 2025.